Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab ; volume:11 ; number:4 ; day:14 ; month:5 ; year:2021 ; pages:1265-1275 ; date:8.2021
Dermatology and therapy ; 11, Heft 4 (14.5.2021), 1265-1275, 8.2021
- Creator
-
Lambert, Jo
Hansen, Jes Birger
Sohrt, Anne
Puig, Luis
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-021-00545-5
- URN
-
urn:nbn:de:101:1-2021102718543042670458
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lambert, Jo
- Hansen, Jes Birger
- Sohrt, Anne
- Puig, Luis
- SpringerLink (Online service)
Other Objects (12)
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Dermatology : with 281 tables
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Pediatric dermatology : with 29 tables
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)
Atlas of dermatology with differential diagnoses
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Dermatology : with 281 tables
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Pediatric dermatology : with 29 tables
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)
Atlas of dermatology with differential diagnoses
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Dermatology : with 281 tables
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Pediatric dermatology : with 29 tables
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)
Atlas of dermatology with differential diagnoses
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)